No Detail Found!

Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.

Author(s)
Sarwat Iqbal Department of Medicine, Shalamar Institute of Health Sciences (SIHS), Lahore, Pakistan
Muhammad Haroon Yousuf Department of Medicine, Shalamar Institute of Health Sciences (SIHS), Lahore, Pakistan
Ayesha Raza Department of Medicine, Shalamar Institute of Health Sciences (SIHS), Lahore, Pakistan
Muhammmad Iftikhar Yousaf Department of Medicine, Shalamar Institute of Health Sciences (SIHS), Lahore, Pakistan
Abstract
Objective: To determine frequency and pattern of adverse events reporting in a subset of Pakistani population being treated for chronic hepatitis C with sofosbuvir combination therapy. Study Design: Descriptive study. Place and Duration of Study: Department of Medicine, Gastroenterology Division, Shalamar Hospital, Lahore, from September 2015 to May 2016. Methodology: Patients who were offered sofosbuvir therapy for treatment of chronic hepatitis C were randomly enrolled. The study subset included both treatment naïve as well as retreatment groups. Patients were screened for subjective as well as objective evidence of adverse events at regular intervals. Frequency was determined. Results: Among 196 patients with chronic hepatitis C, 192 patients received dual therapy consisting of ribavirin and sofosbuvir. The most frequent complaints in these subjects were fatigue, fever, myalgias and nausea accounting for 55%, 42%, 44.2% and 50%, respectively. Twenty-seven percent of patients reported with drop in hemoglobin of >2g/dl, while absolute neutropenia and moderate to severe thrombocytopenia was observed in 3% and 5% of patients, respectively. One patient died as a result of severe pancytopenia. Later derangements were all observed in patients with decompensated disease. Conclusion: Sofosbuvir showed less severe adverse effects in terms of symptomatology and less frequent neutropenia and thrombocytopenia as compared to previous regimens. Careful monitoring is required, especially in those with decompensated liver disease.
Publication Details
Page(s) 146-149
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 2, Year: 2018

Request the full text from PASTIC

References
ASpecial Meeting Review, 2013.Edition: Advances in the treatment of hepatitis C virus infection from EASL 2013,Gastroenterol Hepatol 9 1 -18
MorenoC,HezodeC,MarcellinP,BourgeoisS,FrancqueS,SamuelD, 2015.Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4,J Hepatol 62 1047 -55
ZeuzemS,DusheikoGM,SalupereR,MangiaA,FlisiakR,HylandRH, 2014.Sofosbuvir and ribavirin in HCV genotypes 2 and 3,N Engl J Med 370 1993 -2001
SulkowskiMS,Rodriguez-TorresM,LalezariJP, 2013.All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Presented at: 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD, -
AfdhalN,ReddyKR,NelsonDR, 2014.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection,N Engl J Med 370 1483 -93
AfdhalN,ZeuzemS,KwoP, 2014.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection,N Engl J Med 370 1889 -98
KowdleyKV,GordonSC,ReddyKR, 2014.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis,N Engl J Med 370 1879 -88
2014.Hepatitis C treatment gets into a new gear,J Coll Physicians Surg Pak 24 879 -81
BansalS,SingalAK,McGuireBM,AnandBS, 2015.Impact of all oral anti-hepatitis C virus therapy: A meta-analysis,World J Hepatol 7 806 -13
.December 2013, -
OsinusiA,MeissnerEG,LeeYJ,BonD,HeytensL,NelsonA, 2013.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial,JAMA 310 804 -11
ErmisF,TasciES, 2015.New treatment strategies for hepatitis C infection,World J Hepatol 7 2100 -09
De FranceschiL,FattovichG,TurriniF, 2000.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage,Hepatology 31 997 -1004
FarooqiJI,AlamA,AbbasZ,NaqviAB,ZuberiBF,NawazAA, 2016.Hep-net opinion about the management of patients with chronic hepatitis C in Pakistan in the era of available DAA,J Postgrad Med Inst 30 6 -14
Loustaud-RattiV,Debette-GratienM,JacquesJ,AlainS,MarquetP,SautereauD, 2016.Ribavirin: Past, present and future,World J Hepatol 8 123 -30
DrugAdministration, ., -
DrugAdministration, ., -
CadaDJ,Jasen CongCJ,DanialE., 2014.Formulary drug reviews Sofosbuvir,Baker Hosp Pharm 49 466 -78
0

Citations

0

Downloads

93

Views